Show simple item record

dc.contributor.authorSanderson, A
dc.contributor.authorBonington, Suzanne C
dc.contributor.authorCarrington, Bernadette M
dc.contributor.authorAlison, D L
dc.contributor.authorSpencer, J A
dc.date.accessioned2009-09-07T10:24:46Z
dc.date.available2009-09-07T10:24:46Z
dc.date.issued2002-09
dc.identifier.citationCerebral metastasis and other cerebral events in women with ovarian cancer. 2002, 57 (9):815-9 Clin Radiolen
dc.identifier.issn0009-9260
dc.identifier.pmid12384107
dc.identifier.doi10.1053/crad.2001.0965
dc.identifier.urihttp://hdl.handle.net/10541/79975
dc.description.abstractAIM: To determine the incidence, imaging findings and prognostic significance of cerebral metastases and other cerebral events in women with ovarian cancer. METHOD: A 5-year retrospective review of all women with ovarian cancer who had cranial imaging was undertaken at two major gynaecological oncology centers. RESULTS: Of 1222 women under clinical review, 78 underwent cranial imaging and 13 (1.1%) had cerebral metastasis. Computed tomography (CT) was diagnostic of parenchymal disease in 12 and magnetic resonance imaging (MRI) showed leptomeningeal disease in two. The women were aged between 23 and 73 years and all had stage III or IV disease at presentation. Cerebral metastasis occurred at 6-60 months from initial diagnosis, with death occurring predominantly within 12 months, but with five survivors at 4-45 months. Of the remaining 65 women, 10 had cerebrovascular disease and three had unrelated lesions. CONCLUSION: Cerebral metastasis remains a rare event in women with ovarian cancer but may be an isolated late event associated with survival beyond a year after neurosurgery and chemotherapy. CT should be the first investigation as the incidence of cerebrovascular disease is similar to that of metastatic disease.
dc.language.isoenen
dc.subjectBrain Canceren
dc.subjectOvarian Canceren
dc.subjectCancer Stagingen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshBrain Neoplasms
dc.subject.meshEngland
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshIncidence
dc.subject.meshMagnetic Resonance Imaging
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Staging
dc.subject.meshOvarian Neoplasms
dc.subject.meshPrognosis
dc.subject.meshRetrospective Studies
dc.subject.meshSurvival Rate
dc.subject.meshTomography, X-Ray Computed
dc.subject.meshTreatment Outcome
dc.titleCerebral metastasis and other cerebral events in women with ovarian cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Radiology and Medical Oncology, St James's University Hospital, Leeds, UK.en
dc.identifier.journalClinical Radiologyen
html.description.abstractAIM: To determine the incidence, imaging findings and prognostic significance of cerebral metastases and other cerebral events in women with ovarian cancer. METHOD: A 5-year retrospective review of all women with ovarian cancer who had cranial imaging was undertaken at two major gynaecological oncology centers. RESULTS: Of 1222 women under clinical review, 78 underwent cranial imaging and 13 (1.1%) had cerebral metastasis. Computed tomography (CT) was diagnostic of parenchymal disease in 12 and magnetic resonance imaging (MRI) showed leptomeningeal disease in two. The women were aged between 23 and 73 years and all had stage III or IV disease at presentation. Cerebral metastasis occurred at 6-60 months from initial diagnosis, with death occurring predominantly within 12 months, but with five survivors at 4-45 months. Of the remaining 65 women, 10 had cerebrovascular disease and three had unrelated lesions. CONCLUSION: Cerebral metastasis remains a rare event in women with ovarian cancer but may be an isolated late event associated with survival beyond a year after neurosurgery and chemotherapy. CT should be the first investigation as the incidence of cerebrovascular disease is similar to that of metastatic disease.


This item appears in the following Collection(s)

Show simple item record